Isomorphic Labs has not filed a registration statement for an IPO and remains a private, Alphabet-backed company; there is no indication of a spin-off or independent listing in any reporting found as of the latest site review. The AI drug-discovery company, spun out of Google DeepMind in 2021 around the Nobel Prize-winning AlphaFold protein-structure models, raised its first external funding round of $600 million in March 2025, led by Thrive Capital, followed by a $2.1 billion round in May 2026 -- again led by Thrive Capital, with Alphabet, Temasek, Capital G, and the UK Sovereign AI Fund participating -- which BioSpace called the second-largest biotech funding round ever, after Altos Labs's $3 billion round in 2022. On August 5, 2026, Alphabet announced a broader AI leadership reshuffle in which cofounder and chief executive Demis Hassabis gave up day-to-day management of Google DeepMind to become the unit's chairman and Alphabet's chief scientist; in a note to staff reported by Fortune, Hassabis said he would spend more time at Isomorphic Labs, which he has called the top application of AI for improving human health, and Axios reported he will 'continue to lead Isomorphic Labs.' As of the latest site review, Isomorphic has not disclosed a drug candidate or reached the clinic, though its president told Fortune in July 2025 that human trials focused on oncology were 'very close.' Track SEC EDGAR and Isomorphic Labs's own newsroom directly, not rumors or secondary-market chatter.
segmara.com publishes educational private-market context and can route limited interest into account-based private follow-up. Public pages do not create an offer, allocation, payment instruction, investment advice, or issuer-affiliated workflow.
Key points
A biotech with a Nobel Prize behind it and no pipeline drug in the clinic
Isomorphic Labs was founded in 2021 as a spin-out of Google DeepMind, built around the AlphaFold family of models that predict the 3D structure of proteins, DNA, and RNA -- work that won DeepMind cofounder Demis Hassabis and colleague John Jumper the 2024 Nobel Prize in Chemistry. Rather than targeting a single disease, Isomorphic's AI drug-design platform is meant to work across therapeutic areas, and the company signed early paid partnerships with Eli Lilly ($45 million upfront, up to $1.7 billion in milestones) and Novartis ($37.5 million upfront, up to $1.2 billion in milestones) in January 2024 to apply that platform to their own drug targets.
As of the latest site review, Isomorphic has not disclosed an internal drug candidate or reached human trials on its own pipeline, which it has said focuses on oncology and immunology. Isomorphic's president, Colin Murdoch, told Fortune in July 2025 that human trials were 'the next big milestone' and that the company was 'staffing up' in anticipation, calling that step 'very close.'
Two enormous outside rounds, with Alphabet still in the room
For its first several years, Isomorphic was funded entirely by Alphabet. That changed in March 2025, when Reuters reported the company had raised $600 million in its first-ever external funding round, led by Thrive Capital. Just over a year later, on May 12, 2026, Isomorphic announced a $2.1 billion round -- again led by Thrive Capital, with Alphabet itself, Temasek, Capital G, and the UK Sovereign AI Fund all participating -- which BioSpace's PitchBook-sourced analysis called the second-largest biotech funding round ever, trailing only Altos Labs's $3 billion raise in 2022.
Neither round disclosed a valuation. PitchBook analyst Ben Zercher told BioSpace that Isomorphic's ability to raise at that scale without a disclosed pipeline molecule reflects its 'Alphabet backing and Google DeepMind halo' more than typical biotech investing criteria, which have otherwise shifted toward more clinically advanced, de-risked programs.
A CEO who just said he's doing more of this, not less
On August 5, 2026, Alphabet announced a reshuffle of its AI leadership: Hassabis gave up the CEO title at Google DeepMind to become the unit's chairman and Alphabet's chief scientist, with deputy Koray Kavukcuoglu taking over daily operations and reporting directly to Alphabet CEO Sundar Pichai. In a note to staff reported by Fortune, Hassabis said he would spend more time at Isomorphic Labs, which he has called the top application of AI for improving human health; Axios reported separately that Hassabis 'will also add the title of chief scientist for Google parent company Alphabet and also continue to lead Isomorphic Labs.'
That is the opposite of the signal a founder typically sends ahead of spinning off or separately listing a company: rather than stepping back from Isomorphic to prepare it for independence, its CEO is stepping toward it. Nothing here substitutes for a filing, and any specific 'Isomorphic Labs IPO date' circulating online remains speculation with no public statement, spin-off announcement, or S-1 behind it.
Private-share data lens
Public round-by-round marks are incomplete for this company. Segmara shows the listing mark and keeps the seed-to-IPO analysis focused on verifiable funding, tender, or secondary signals.
Segmara markRequest quote
Indicative listing context
Stage
Date
Valuation / price signal
Why it matters
Seed / early
Private
Not reliably public
Do not invent a seed price when the source set is thin.
Growth rounds
Private
Company and market sources vary
Use public sources, official releases, and private follow-up.
Segmara listing
Current
Request quote
Indicative context for starting the review process.
IPO status
Current
No public ticker shown here
Visitors start with private-market review on Segmara.
Seed-to-IPO path
Illustrative completeness map. Longer bars mean stronger public data or more useful current pricing context, not lower risk.
Early data22%
Growth data46%
Segmara mark68%
IPO/public18%
AI-ready data summary
A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.
Metric
Value
Context
Canonical route
/blog/when-will-isomorphic-labs-ipo
Stable URL path for AI and search extraction.
Article title
When Will Isomorphic Labs IPO? Its CEO Just Stepped Back From Google DeepMind to Spend More Time Here.
Main page topic.
Attached public sources
6
Number of citation links rendered at the bottom of the article.
Segmara listed companies
53
Live private-company listings in the public catalogue.
Priced listings
39
Catalogue listings with visible indicative or direct marks.
Request-quote listings
14
Catalogue listings where a public price is intentionally not invented.
Company
Isomorphic Labs
Named company covered by this buying guide.
Symbol label
ISOM
Segmara display symbol; not a public stock ticker unless separately stated.
Sector
AI Drug Discovery
Catalogue sector used for comparison and internal linking.
Listing structure
Request
How the listing is categorized on Segmara.
Segmara mark
Request quote
Visible listing mark or request-quote state.
Sector peer count
1
Number of live Segmara listings in AI Drug Discovery.
Structure peer count
14
Number of live Segmara listings categorized as Request.
Data fingerprint chart
Price visibility24%
Request quote listing
Source depth88%
6 source links
Sector peer signal42%
1 AI Drug Discovery listing(s)
Structure specificity48%
Request
Stage
Timing
Price / valuation signal
Interpretation
Formation
Private
Early ownership
The first value creation happens before ordinary public-market access.
Growth rounds
Private
Institutional repricing
Later rounds and tenders create the price history buyers study.
Segmara listing
Current
Request quote
Retail buyers can start from the public Segmara listing.
Exit path
Future
IPO, tender, acquisition, or continued private status
Liquidity timing remains company-specific.
Chart metric
Score
Interpretation
Price visibility
24 / 100
Request quote listing
Source depth
88 / 100
6 source links
Sector peer signal
42 / 100
1 AI Drug Discovery listing(s)
Structure specificity
48 / 100
Request
Analytical lens
Search intent
The search behind 'When Will Isomorphic Labs IPO? Its CEO Just Stepped Back From Google DeepMind to Spend More Time Here.' is an access-intent query. People want to know where they can start interest in Isomorphic Labs private-market exposure without needing a private equity relationship, fund connection, or insider network.
Access path
segmara.com turns that search into a simple path: browse the listing, create an account, choose the company, and start the private-share inquiry. Final pricing and availability still depend on the route, but the starting point is public and straightforward.
Segmara role
Segmara works as a private-market access layer for interested visitors. The site helps visitors discover ai drug discovery categories that were previously hard to research and moves them into an account-based inquiry in a few steps.
Private-share path map
From gatekept to accessible
BrowseRetail investor finds a private-company listing.
AccountBuyer creates one Segmara account.
RequestBuyer starts the private-share purchase request.
CloseAvailability, price, approvals, and final terms are handled privately.
Access-friction chart
Illustrative map of where the old private-market process was hardest and where Segmara makes the starting point easier.
Old-market frictionPrivate networks and institutional access
Segmara discoveryPublic listings retail buyers can browse
Account workflowOne account to start the purchase request
Private closeFinal terms handled after buyer interest
How private-share access starts on Segmara
No S-1 or F-1 exists for Isomorphic Labs on SEC EDGAR as of the latest site review, and no reporting found describes a spin-off or independent-listing plan; the company remains majority-backed by Alphabet, which participated in its most recent funding round.
Isomorphic raised its first outside capital, $600 million, in March 2025, led by Thrive Capital, then closed a $2.1 billion round in May 2026 -- also led by Thrive, with Alphabet, Temasek, Capital G, and the UK Sovereign AI Fund participating -- which BioSpace described as the second-largest biotech funding round on record.
On August 5, 2026, cofounder and CEO Demis Hassabis stepped back from day-to-day leadership of Google DeepMind to become its chairman and Alphabet's chief scientist, saying in a staff note that he would spend more time at Isomorphic Labs; Axios reported he will continue to lead the company, even as its president told Fortune in July 2025 that oncology-focused human trials were 'very close.'
Risk notes
Rumor risk: unofficial dates, valuations, or funding details circulating on social media or forums are frequently wrong or outdated and should not be treated as confirmation of anything.
Illiquidity risk: any private-market interest, indicative marks, or pre-IPO share arrangements in a company that has not filed to go public can be difficult to exit and may not reflect a tradable price.
Timing risk: a company can pause, restart, or abandon IPO preparation at any stage, including after a confidential draft filing, so no step before an effective registration statement guarantees a listing will occur.
Can retail investors track private-company shares on Segmara?
Yes. Visitors can start with the free Isomorphic Labs tracker using email only, then decide whether a private follow-up makes sense. Availability, eligibility, pricing, allocation, transfer approval, documents, and final terms can still vary by route.
Why was this market historically hard for retail investors to reach?
Private-company share access has often moved through private equity firms, venture funds, insiders, institutions, and relationship-driven secondary networks. Segmara makes the starting point simpler: visitors can follow named private-company interest before any account, document upload, or payment step.
What is the easiest next step?
Open the free Isomorphic Labs tracker first. It is email-only and keeps the public step narrow while final availability, pricing, eligibility, and terms are handled only through private follow-up.
Has Isomorphic Labs confirmed an IPO date?
No, and no reporting found as of the latest site review even raises the possibility. The company has not filed an S-1 or F-1, has not been spun off from Alphabet as an independent entity, and Alphabet itself participated in Isomorphic's most recent $2.1 billion funding round.
What is Isomorphic Labs worth?
No public valuation figure has been disclosed for either of Isomorphic's external funding rounds -- the $600 million raised in March 2025 or the $2.1 billion raised in May 2026. BioSpace described the 2026 round as the second-largest biotech funding round ever, behind Altos Labs's $3 billion raise in 2022.
Is Isomorphic Labs still an Alphabet company?
Yes. Alphabet participated as an investor in Isomorphic's May 2026 funding round alongside Thrive Capital, Temasek, Capital G, and the UK Sovereign AI Fund, and cofounder and CEO Demis Hassabis said in August 2026 that he would spend more time running Isomorphic even as he took on a new Alphabet-wide chief scientist role -- the opposite signal from an executive preparing to spin off or separately list a company.
Can I buy Isomorphic Labs shares before an IPO?
Not through a public exchange. Isomorphic Labs is a private company, and any private-share offer you encounter should be verified independently before you rely on it. Segmara does not sell, broker, or arrange purchases of Isomorphic Labs shares.
Next step
Track private-market prices free.
If this article helped explain Isomorphic Labs, start with the free tracker: indicative pre-IPO marks by email. No card, no documents, no brokerage account, and no allocation promise.
When a full account makes sense, Segmara can route limited interest into an account-based private follow-up. Availability, pricing, eligibility, allocation, transfer approval, liquidity, and final terms can vary by company and route.